drugset
drugset / Trial / NCT02914990

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

NCT02914990 ↗

Phase 1 Completed 36 enrolled Betta Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to evaluate the safety and tolerability of BPI-15086.

Timeline

Start
2016-12-29
Primary completion
2019-03-07
Completion
2019-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BPI-15086 Unknown 25 mg Oral

Indications

non-small cell lung carcinoma